![First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/093c9d06-d2c1-4473-9680-392eb18a9ce3/gr1_lrg.gif)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet
![Exogenous Cushing's syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits - ScienceDirect Exogenous Cushing's syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2214624517300059-gr1.jpg)
Exogenous Cushing's syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits - ScienceDirect
![Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study | The BMJ Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study | The BMJ](https://www.bmj.com/content/bmj/357/bmj.j1415/F1.large.jpg)